Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Americas must redouble HIV testing and treatment efforts:

This article was originally published in Clinica

Executive Summary

The Pan American Health Organization is putting pressure on the "many governments of the Americas" who must redouble their efforts if they are to achieve their HIV/AIDS testing and treatment targets. The so-called Nuevo Leon Declaration, signed by 34 countries in January 2004, pledged to strive to meet 100% of the HIV/AIDS healthcare needs of the continent, with at least 600,000 people covered by the end of 2005. One year on, many countries have achieved coverage of less than 50%. One of the problems is that half of the estimated 3.14 million people infected with HIV in the Americas are not aware of the infection - the official figure stands at around 1.6 million. "Stigma and discrimination are preventing people from getting tested," says PAHO.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT054017

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel